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MK-7246, an antagonist of a chemoattractant receptor on T helper 
type 2 (Th2) cells, is being developed for the treatment of respi-
ratory diseases.1,2 The metabolism of MK-7246 was studied in 
both preclinical species and in hepatocytes. After oral administra-
tion of [3H]MK-7246 in bile-duct-cannulated rats, ~84% of the 
administered radioactivity was recovered, with 77% excreted in 
the bile. Biotransformation was the major route of elimination 
of MK-7246. Less than 3% of the radioactive dose was excreted 
as unchanged parent drug in rat bile, and the acyl glucuronide 
M3 accounted for ~90% of the radioactivity in the bile. These 
data suggest that direct glucuronidation is the major elimination 
route for MK-7246 in rats. In human hepatocytes, M3 was the 
major metabolite observed; minor metabolites included an oxida-
tive metabolite and a glucuronide of an oxidative metabolite. The 
metabolites observed in rat hepatocytes were qualitatively similar 
to those observed in human hepatocytes; M3 was also the major 
metabolite observed in rat hepatocytes (Merck, unpublished data, 
data on file). Taken together, these data suggest that glucuronida-
tion is probably the major metabolic pathway in humans.
Uridine 5′-diphosphate-glucuronosyltransferases (UGTs) 
catalyze glucuronidation of various endogenous substances 
and xenobiotics. The UGT family of phase II enzymes consists 
of the subfamilies UGT1A, UGT2A, UGT2B, UGT3A, and 
UGT8. Some of the UGT genes are highly polymorphic and are 
associated with interindividual variability in pharmacokinetics 
of certain therapeutic agents.3 For example, patients with the 
UGT1A1*28 mutation were associated with a 30–50% lower 
glucuronidation ratio of SN-38 glucuronide to SN-38, an active 
metabolite of irinotecan; the ratio is correlated with irinotecan-
induced diarrhea.4–6 Oral clearance of zidovudine was shown 
to be approximately twofold higher in UGT2B7*1c carriers than 
in noncarriers.7 The UGT2B15 D85Y polymorphism has been 
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UGT2B17 Genetic Polymorphisms Dramatically 
Affect the Pharmacokinetics of MK-7246 in 
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MK-7246, an antagonist of the chemoattractant receptor on T helper type 2 (Th2) cells, is being developed for the 
treatment of respiratory diseases. In a first-in-human study, we investigated whether genetic polymorphisms 
contributed to the marked intersubject variability in the pharmacokinetics of MK-7246 and its glucuronide metabolite 
M3. Results from in vitro enzyme kinetic studies suggested that UGT2B17 is probably the major enzyme responsible 
for MK-7246 metabolism in both the liver and the intestine. As compared with those with the UGT2B17*1/*1 wild-type 
genotype, UGT2B17*2/*2 carriers, who possess no UGT2B17 protein, had 25- and 82-fold greater mean dose-normalized 
values of area under the plasma concentration–time curve (AUC) and peak concentration of MK-7246, respectively, 
and a 24-fold lower M3-to-MK-7246 AUC ratio. The apparent half-life of MK-7246 was not as variable between these 
two genotypes. Therefore, the highly variable pharmacokinetics of MK-7246 is attributable primarily to the impact of 
UGT2B17 genetic polymorphisms and extensive first-pass metabolism of MK-7246.
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identified as a major determinant of oxazepam clearance; median 
oxazepam oral clearance was ~50% lower in subjects with 85YY 
than in those with 85DD.8 Overall, the effects of genetic poly-
morphisms of UGT enzymes on the pharmacokinetics of drugs 
have generally been found to be less than twofold.
The first-in-human study of the pharmacokinetics of MK-7246 
showed high variability. The objective of this study was to identify 
the UGT responsible for MK-7246 glucuronidation and to investi-
gate whether UGT genetic polymorphisms are responsible for the 
large variability observed in MK-7246 pharmacokinetics.
Results
Variability of MK-7246 pharmacokinetics as observed in the 
first-in-human study
In response to oral administration of single doses of MK-7246, 
large intersubject variability in MK-7246 plasma concentrations 
was observed; the coefficient of variation (CV) of area under 
the plasma concentration–time curve from time 0 to infinity 
(AUC0→∞) of MK-7246 ranged from 74 to 177%. At doses <20 mg, 
only two subjects had detectable concentrations of MK-7246 in 
plasma samples collected at 24 h after administration. Individual 
plasma concentration–time profiles of MK-7246 after a single 
40-mg dose are shown in Figure 1a,b. Study subjects could be 
categorized into high- and low-exposure groups based on their 
MK-7246 plasma concentrations, and intersubject variability 
within these groups was <20%. Plasma drug concentrations of sub-
jects in the high- and low-exposure groups remained high and low, 
respectively, throughout the entire dose range tested. The values of 
the M3-to-MK-7246 AUC ratio were ~0.5 and ~12 in subjects with 
high and low MK-7246 plasma concentrations, respectively.
MK-7246 glucuronidation
The apparent difference in metabolite-to-parent AUC ratio 
between the low- and high-exposure groups indicated that the 
pharmacokinetic variability was probably related to glucuronida-
tion of MK-7246. To determine which of the UGTs were capable 
of metabolizing MK-7246 to M3, we screened 12 recombinant 
human UGTs for MK-7246 glucuronidation activity at 5 and 
50 μmol/l MK-7246. All UGTs were capable of forming the acyl 
glucuronide M3 (Figure 2). Among the 12 enzymes, UGT1A4, 
UGT1A6, UGT1A7, UGT1A10, UGT2B4, and UGT2B15 were 
the least active, and UGT1A1, UGT1A3, UGT2B17, UGT1A8, 
UGT1A9, and UGT2B7 were the most active, based on the peak 
area ratios. Subsequently, enzyme kinetics studies were performed 
for the six most active isoforms. MK-7246 glucuronidation by the 
six isoforms, human liver microsomes (HLMs), and human intes-
tinal microsomes (HIMs) exhibited hyperbolic Michaelis–Menten 
kinetics. The kinetic parameters substrate concentration at half-
maximal velocity (Km) and maximal velocity (Vmax) are summa-
rized in Table 1. Recombinant UGT2B17 exhibited high affinity for 
MK-7246, with a Km value of 3.2 μmol/l, which was comparable to 
the Km value generated in HIMs. Km values of other recombinant 
UGTs were ~25- to 30-fold greater as compared with recombinant 
UGT2B17. In addition, recombinant UGT2B17 was also the only 
enzyme that had a lower Km value for MK-7246 than the value gen-
erated in HLMs. The Km values of other recombinant UGTs were 
more than fourfold greater than the value generated in HLMs.
effect of UGT2B17 polymorphism on the pharmacokinetics of 
MK-7246 and M3
The results of the in vitro glucuronidation studies indicate 
that UGT2B17 could be the major UGT responsible for acyl 
  glucuronidation of MK-7246, in both the liver and the intestine. 
To investigate whether UGT2B17 genetic polymorphisms are 
associated with the high variability observed in MK-7246 phar-
macokinetics, we conducted a genetic analysis. Of the 16 subjects 
who participated in the first-in-human study, 13 consented to be 
genotyped. These subjects were allocated to one of the three groups 
according to their UGT2B17 genotypes (Table 2). There was no 
statistically significant difference in mean age, height, or weight 
between subjects with at least one UGT2B17*1 allele and subjects 
with the UGT2B17*2/*2 genotype (recessive model; P < 0.2). 
Time (h)
1
10
100
1,000
Time (h)
M
K
-
7
2
4
6
 
p
l
a
s
m
a
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
 
(
n
m
o
l
/
l
)
0
200
400
600
800
1,000
01 22 43 64 8 01 22 43 64 8
01 22 43 64 8 01 22 43 64 8
1
10
100
1,000 ab
Figure 1  Plasma concentration–time profiles of MK-7246 after administration of a single 40-mg dose of MK-7246 in the fasted state in individuals in panels (a) 
A and (b) B of the first-in-human study. Eight subjects, including two who received the placebo, participated in each panel. Each symbol and line represents a 
separate individual who received MK-7246 within each panel.articles
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The effects of UGT2B17 polymorphisms on the exposure levels 
of MK-7246 and M3 at different doses are shown in Table 3. As 
compared with subjects with at least one UGT2B17*1 allele, those 
with the UGT2B17*2/*2 genotype had much higher MK-7246 con-
centrations. In response to administration of doses ranging from 1 
to 160 mg, the plasma concentrations of M3 were generally lower 
in the subjects with the UGT2B17*2/*2 genotype than in those 
with at least one UGT2B17*1 allele. M3 concentration levels were 
below the limit of detection in subjects with the UGT2B17*2/*2 
genotype after administration of doses <10 mg. In addition, the 
M3-to-MK-7246 AUC ratios in subjects with the UGT2B17*2/*2 
genotype were consistently <1 throughout the entire dose range.
The 13 subjects who were genotyped participated in the first-
in-human study and received different dose levels. To compare 
the effects of UGT2B17 polymorphisms among genotype groups, 
the plasma concentrations and pharmacokinetic parameters of 
MK-7246 and M3 were normalized to the 40-mg dose for nine 
subjects, to the 20-mg dose for two subjects, and to the 80-mg dose 
for two subjects. The mean dose-normalized AUC0-∞ of MK-7246 
was 25-fold greater in subjects with the UGT2B17*2/*2 genotype 
than in those with the UGT2B17*1/*1 genotype and 10-fold higher 
than in heterozygous subjects (Figure 3, Table 4). The intersub-
ject variability in dose-normalized AUC0-∞ of MK-7246 within 
the heterozygous genotype group was high, with a CV of 93%; 
the CVs with respect to other genotype groups were <20%. The 
mean dose-normalized peak concentration in plasma (Cmax) of 
MK-7246 was ~82-fold greater in subjects with the UGT2B17*2/*2 
genotype than in those with the UGT2B17*1/*1 genotype and 
~19-fold greater than in heterozygous subjects. The intersubject 
variability in dose-normalized Cmax of MK-7246 within the het-
erozygous genotype group was high, with a CV of 103%; the CVs 
with respect to other genotype groups were <35%. The effects of 
the UGT2B17 genotype on time to Cmax (tmax) and terminal half-
life (t1/2) of MK-7246 were less dramatic. There was a tendency 
toward shorter tmax and t1/2 in subjects with the UGT2B17*2/*2 
genotype. The tmax and t1/2 of MK-7246 varied in the range of 
~2- and ~2.5-fold between individual subjects within each of the 
three genotype groups.
The associations between UGT2B17 genotypes and the phar-
macokinetics of M3 at the dose levels studied were not statisti-
cally significant (Figure 3; Table 4). Although greater AUC0-∞ 
values were observed in heterozygous subjects, the mean dose-
normalized AUC0-∞ of the acyl glucuronide M3 was similar in 
subjects with the UGT2B17*2/*2 genotype and those with the 
UGT2B17*1/*1 genotype. The mean Cmax of M3 was lower in 
subjects with the UGT2B17*1/*1 genotype than in those in other 
genotype groups. The dose-normalized AUC0-∞ and Cmax of M3 
were less variable in subjects with the UGT2B17*1/*1 genotype 
as compared with subjects in other genotype groups. The CVs 
of AUC0–∞ of M3 in the UGT2B17*1/*1, UGT2B17*1/*2, and 
UGT2B17*2/*2 genotype groups were 20, 44, and 39%, respec-
tively, while the corresponding values of CVs with respect to 
Cmax were 15, 33, and 52%, respectively. The mean t1/2 of M3 
in all genotypes was similar to the corresponding mean t1/2 of 
MK-7246. The median tmax of M3 was delayed relative to the 
median tmax of MK-7246 in subjects with the UGT2B17*1/*1 
and heterozygous genotypes.
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Figure 2  Formation of acyl glucuronide M3 by recombinant human 
UGTs. MK-7246 at 5 and 50 μmol/l MK-7246 were incubated with UGTs in 
the presence of UDPGA for 90 min. Each bar and error bar represents the 
mean and standard deviation, respectively, of determinations carried out 
in triplicate. HLM, human liver microsome; UDPGA, uridine 5′-diphospho-
glucuronic acid; UGT, uridine 5′-diphosphate-glucuronosyltransferase.
table 1  Kinetic parameters for MK-7246 glucuronidation by 
human liver microsomes, human intestinal microsomes, and 
recombinant uGts
protein concentration 
(mg/ml)
Vmax 
(pmol/min/mg) Km (μmol/l)
HLMs 0.25 251.9 20.7
HIMs 0.25 416.3 6.1
UGT1A1 0.5 134.6 91.5
UGT1A3 0.5 109.8 83.4
UGT1A8 0.5 42.5 79
UGT1A9 0.5 70.7 96.3
UGT2B7 1 44.3 83
UGT2B17 0.5 135.1 3.2
The unbound fraction of MK-7246 in human liver microsomes (1 mg/ml) was 0.867.
HIM, human intestinal microsome; HLM, human liver microsome; Km, substrate 
concentration at half-maximal velocity; UGT, uridine 5′-diphosphate-
glucuronosyltransferase; Vmax, maximal velocity.
table 2  Demographics of all study subjects and subjects 
genotyped for UGT2B17 genotype
Age (year) Weight (kg) height (cm) BMI (kg/cm2)
UGT2B17*1/*1 
(n = 4)
37.5 ± 6.2 85.1 ± 6.9 173.3 ± 10.6 28.4 ± 2.1
UGT2B17*1/*2 
(n = 5)
35.4 ± 3.8 77.9 ± 4.7 179.0 ± 8.2 24.4 ± 2.8
UGT2B17*2/*2 
(n = 4)
33.5 ± 9.9 83.1 ± 7.9 179.6 ± 5.1 25.7 ± 2.3
UGT2B17*1/*1 
or *1/*2 (n = 9)
36.3 ± 4.8 81.1 ± 6.5 176.4 ± 9.2 26.2 ± 3.1
All subjects 
(n = 16)
34.9 ± 6.8 80.6 ± 7.2 177.2 ± 7.8 25.2 ± 2.8
Values are shown as means ± SD.
BMI, body mass index.articles
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Discussion
The present study shows that the UGT2B17 enzyme is the major 
UGT enzyme responsible for the glucuronidation of MK-7246. 
UGT2B17 genetic polymorphism is associated with the highly var-
iable pharmacokinetics observed in the MK-7246 first-in-human 
study. This study is the first to report that genetic polymorphisms 
of a UGT enzyme can have such a profound effect on the pharma-
cokinetics of a compound in drug development.
The UGT2B17 enzyme is involved in androgen metabolism 
and is capable of metabolizing a variety of xenobiotics including 
several coumarins, anthraquinones, and flavonoids.9 UGT2B17 
messenger RNA (mRNA) is expressed in both the liver and the 
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Figure 3  Dose-normalized individual (N = 13) and mean plasma concentration–time profiles of MK-7246 and its acyl glucuronide metabolite, M3, in UGT2B17 
genotype groups of healthy volunteers after a single dose of MK-7246.
table 3  Mean MK-7246 and M3 exposure following single doses of MK-7246 in relation to UGT2B17 genotype
Dose (mg)
UGT2B17*2/*2 UGT2B17*1/*2 UGT2B17*1/*1
n
AUC0–∞ (μmol/l × h) M3/MK 
ratio n
AUC0–∞ (μmol/l × h) M3/MK 
ratio n
AUC0–∞ (μmol/l × h) M3/MK 
ratio MK-7246 M3 MK-7246 M3 MK-7246 M3
1 1 0.10 ND NA 2 ND ND NA 1 ND ND NA
2 1 0.18 ND NA 1a 0.03b 0.13b 6.6 0 NP NP NA
5 0 NP NP NA 3 0.05b 0.42b 10.4 1 0.003b 0.10b 31.6
10 1 0.89 0.39 0.4 4 0.07b 0.87 29.1c 1 0.01b 0.60b 52.7
20 1 2.88 0.98 0.3 2 0.21 1.99 9.4 1 0.12 1.80 15.3
40 3 5.42 3.09 0.6 4 0.79 4.86 9.2 2 0.25 3.28 13.3
80 1 14.86 3.42 0.2 1 0.62 7.31 10.5 3 0.46 5.35 11.8
160 3 17.34 12.05 0.7 0 NP NP NA 2 1.28 28.23 20.3
320 3 28.72 23.13 0.8 1 1.69 40.20 22.2 2 1.21 24.71 20.5
Mean data are reported when appropriate.
AUC0–∞, area under the plasma concentration–time curve from time 0 to infinity; MK, MK-7246; n, number of subjects in each genotype at the dose studied; NA, M3/MK ratio could 
not be calculated due to lack of either MK-7246 or M3 exposure; ND, not detectable; NP, not present.
aM3 was detectable in three UGT2B17*1*2 subjects but MK-7246 was detectable from only one subject. Data from this one subject are reported. bAUC0–last. cM3/MK ratio was 
calculated using AUC0–last.articles
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intestine.10 There are two common alleles of the UGT2B17 
gene. The UGT2B17*1 allele is considered the wild-type allele. 
The UGT2B17*2 allele has a deletion of 150 kb spanning the 
entire UGT2B17 gene11 and resulting in complete absence of 
UGT2B17 protein. The frequency of the UGT2B17*2/*2 geno-
type varies significantly among ethnic groups. For example, the 
frequency of the UGT2B17*2/*2 genotype was reported to be 
~9–15% in Caucasians,12 67% in a Korean population,13 and 
>80% in a Japanese population.14 The UGT2B17*2/*2 geno-
type is strongly associated with urinary testosterone levels; the 
  urinary testosterone/epitestosterone ratio was ~16-fold lower in 
subjects with the UGT2B17*2/*2 genotype than in those with 
the UGT2B17*1/*1 genotype.15
In the MK-7246 first-in-human study, a 20-fold difference 
in mean exposure of MK-7246 was observed between subjects 
carrying at least one UGT2B17*1 allele and those with the 
UGT2B17*2/*2 genotype. This is probably attributable to the 
complete absence of UGT2B17 enzyme activity in the subjects 
with the UGT2B17*2/*2 genotype. In subjects with this geno-
type, Cmax values of MK-7246 were ~80-fold greater than in 
subjects with at least one UGT2B17*1 allele, but the values of 
apparent t1/2 were similar. This indicates that the UGT2B17*2 
polymorphism affects mainly first-pass metabolism of MK-7246. 
These findings may be due to potentially high expression of 
UGT2B17 in the intestine relative to other UGTs. A recent 
study showed that UGT2B17 mRNA expression in the intes-
tine was ~13-fold higher than in the liver and that UGT2B17 
mRNA had the highest expression in the intestine among all 
UGT mRNAs.10 In addition, UGT2B17 mRNA was not highly 
expressed in the liver.10 Furthermore, MK-7246 is a specific sub-
strate for UGT2B17, as shown by in vitro UGT studies. The high 
affinity of MK-7246 for UGT2B17 relative to the other UGTs 
tested, and the potentially high expression of UGT2B17 in the 
intestine, may result in extensive metabolism of MK-7246 in the 
intestine in subjects with at least one UGT2B17*1 allele, thereby 
contributing to the large difference in MK-7246 concentrations 
observed among the genotype groups.
Interestingly, the mean apparent t1/2 in subjects with at least 
one UGT2B17*1 allele tends to be longer than in subjects with 
the UGT2B17*2/*2 genotype. This finding appears to be incon-
sistent with the extensive metabolism of MK-7246 but may be 
explained by possible enterohepatic recirculation of MK-7246. 
For example, in subjects with at least one UGT2B17*1 allele, 
MK-7246 was extensively metabolized, thereby forming more 
acyl glucuronide M3; the conversion of M3 to MK-7246 in the 
intestine could lead to reabsorption of MK-7246, thereby pro-
longing the duration for which MK-7246 remains in the body. 
Extensive metabolism of MK-7246 in the intestine in these 
subjects may also contribute to the absence of multiple peaks 
(a signature of enterohepatic circulation) in their plasma con-
centration–time profiles. In subjects with the UGT2B17*2/*2 
genotype, less M3 was formed because of lack of the UGT2B17 
enzyme, and therefore less M3 was available for the recircula-
tion process. Consequently, in subjects with the UGT2B17*2/*2 
genotype, M3 appeared to have a shorter t1/2.
The effects of UGT2B17*2 polymorphism on M3 pharmacoki-
netics were less dramatic. In subjects with the UGT2B17*2/*2 
  genotype, M3 concentrations were undetectable for doses <10 mg. 
As the dose increased, M3 concentrations in these subjects 
increased, but the exposure levels remained at approximately half 
of those observed in subjects with at least one UGT2B17*1 allele. 
This may indicate that other UGT enzymes could be involved in 
MK-7246 glucuronidation; this is likely to occur when MK-7246 
concentrations in the intestine and the liver exceed their Km 
values. For example, on the basis of its known solubility char-
acteristics, we could assume that the 10-mg dose of MK-7246 
was completely dissolved in 250 ml of fluid. Under these condi-
tions, the concentration of MK-7246 in the intestine could reach 
76.8 μmol/l, which would be close to the Km values of UGT1A8 
and UGT2B7. At the 20-mg dose, MK-7246 concentration in the 
intestine could exceed the Km values of all six UGT isoenzymes 
that are capable of metabolizing MK-7246. It is difficult to estimate 
the extent to which these UGT enzymes are involved in MK-7246 
glucuronidation because the protein expressions of these UGTs 
in the tissues and in the recombinant enzyme systems used in 
this study are not known. The difference in M3 concentrations 
between subjects with the UGT2B17*2/*2 genotype and those 
with at least one UGT2B17*1 allele was much less than the differ-
ence observed in MK-7246 concentrations (Table 4). This could 
be due to formation-limited elimination of M3, as indicated by 
the similar values of apparent t1/2 for M3 and MK-7246; M3 con-
centrations in plasma may not reflect the amount of M3 actually 
formed in these subjects because the metabolite was eliminated 
as soon as it was formed.
MK-7246 concentrations in the heterozygous subjects were simi-
lar to those in subjects with the UGT2B17*1/*1 genotype, suggest-
ing that a gene-dose effect was not present. Similar observations 
table 4  Dose-normalized pharmacokinetic variables of MK-7246 
in 13 healthy subjects in relation to UGT2B17 genotype
UGT2B17 
genotype
Cmax  
(nmol/l)
tmax
a 
(h)
t1/2
b  
(h)
AUC0→∞ 
(nmol/l·h)c
AUC0→∞ 
ratio (M3/
MK-7246)
MK-7246
  *1/*1 (n = 4) 0.22 ± 0.08 6 19.9 ± 8.1 5.87 ± 0.84
  *1/*2 (n = 5) 0.94 ± 0.96 4 19.0 ± 9.9 14.66 ± 13.68
  *2/*2 (n = 4) 18.11 ± 5.85 2 10.8 ± 4.4 148.03 ± 25.21
  *1/*1 or  
  *1/*2 (n = 9)
0.62 ± 0.78 6 19.4 ± 8.3 10.75 ± 10.74
M3
  *1/*1 (n = 4) 2.89 ± 0.42 6 16.7 ± 5.1 70.08 ± 13.83 12.02 ± 2.33
  *1/*2 (n = 5) 6.66 ± 2.96 6 15.5 ± 6.5 122.52 ± 40.43 11.82 ± 6.61
  *2/*2 (n = 4) 6.73 ± 3.47 4 12.0 ± 3.2 68.63 ± 26.76 0.49 ± 0.23
  *1/*1 or  
  *1*2 (n = 9)
4.99 ± 2.89 6 16.0 ± 5.5 99.22 ± 40.66 11.91 ± 4.89
Values are shown as mean ± SD unless otherwise stated.
AUC0→∞, area under the plasma concentration–time curve from time 0 to infinity; 
Cmax, peak concentration in plasma; tmax, time to Cmax; t1/2, terminal half-life.
atmax data are given as median. bt1/2 data are given as harmonic mean ± pseudo SD. 
cFor MK-7246, both the Fisher’s exact test for a bimodal genotype categorization and 
the Cochran-Mantel-Haenszel test (UGT2B17*1/*1, *1/*2 and *2/*2 genotypes) were 
run for AUC (P ≤ 0.001).articles
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were reported in a doping test study15 and a study that linked the 
UGT2B17 polymorphism with androgen expression in pubertal 
boys.16 The urinary testosterone glucuronide concentrations and 
urinary testosterone/epitestosterone ratios in the heterozygous 
subjects were similar to those in subjects with the UGT2B17*1/*1 
genotype.15,16 Consistent with these findings, HLMs taken from 
heterozygous subjects had similar relative UGT2B17 mRNA expres-
sion17 and testosterone glucuronidation activity13 as compared 
with microsomes taken from subjects with the UGT2B17*1/*1 gen-
otype. In our study, higher interindividual variability was observed 
within the heterozygous subjects as compared with other genotype 
groups. Two subjects had relatively higher MK-7246 concentra-
tions than the rest of the subjects in the heterozygous genotype 
group. The reason for high variability in this group is not known. 
Other factors (such as the influence of genetic variants) may be 
involved in the elimination of MK-7246. However, the small sam-
ple size in this study hinders further investigation.
In summary, we report that genetic variations in the UGT2B17 
gene dramatically affect the pharmacokinetics of MK-7246 in 
healthy subjects. We found that the large variability in MK-7246 
plasma concentration–time profiles is probably due to the exten-
sive first-pass metabolism in subjects with at least one UGT2B17*1 
allele and the complete absence of the UGT2B17 enzyme in sub-
jects homozygous for the UGT2B17*2 allele. In recent years, sub-
stantial efforts have been made in reducing the risk of drug–drug 
interactions related to cytochrome P450 enzymes and variability 
caused by polymorphic expression of cytochrome P450 enzymes 
(e.g., CYP2D6). According to study reports, drug interactions and 
genetic polymorphisms of UGT enzymes generally cause less than 
twofold alterations in the pharmacokinetic parameters of drugs18; 
this is probably attributable to the overlapping substrate specificity 
of UGT enzymes. As a result, there is currently a move toward 
developing drugs that are cleared through alternative pathways 
such as glucuronidation. Our study results demonstrate that 
marked intersubject variability in healthy subjects could occur 
when a compound is primarily metabolized by glucuronidation, 
especially when the compound is a specific substrate of UGT2B17. 
The effects of UGT2B17 polymorphisms on the pharmacokinetics 
of MK-7246 suggest that the potential effects of a potent inhibi-
tor of UGT2B17 on a concomitant specific UGT2B17 substrate 
cannot be ignored. Therefore, caution should be exercised when a 
compound is primarily eliminated by glucuronidation, and UGT 
phenotyping should be performed to rule out potentially serious 
drug interactions or large variability in pharmacokinetics.
MethoDs
clinical study design. This first-in-human study was a double-blind, 
randomized, placebo-controlled, serial-panel, rising-single-oral-dose 
study in healthy male subjects. The study was designed to evaluate the 
safety, pharmacokinetics, and pharmacodynamics of MK-7246. The 
study and the subsequent pharmacogenetic sample collection were 
approved by the institutional review board of Ziekenhuis Netwerk 
Antwerpen (Antwerp, Belgium). The subjects gave informed consent 
separately for the study and for pharmacogenetic sample collection. 
All procedures were performed in accordance with the principles of 
the Declaration of Helsinki. The study consisted of two panels (A and 
B); each panel had eight subjects. All 16 subjects reported their eth-
nicity as Caucasian. Each subject received single rising doses of 1, 2, 
5, 10, 20, and 40 mg (panel A) or 40 (with or without food), 80, 160, 
and 320 mg (panel B) of MK-7246 or a matching placebo. All doses 
were administered after an 8-h overnight fast, except that subjects in 
panel B who received 40 mg in the fasted state were administered the 
40-mg dose again later during the study after a standard high-fat meal. 
During each treatment period (or dose) in each panel, six subjects 
received MK-7246 and two subjects received placebo in a randomized, 
balanced, blinded fashion. After administration of MK-7246, there 
was a minimum washout period of 7 days before readministration of 
MK-7246 in the subsequent period, for any individual subject. Dosing 
in panel B did not commence until completion of dosing in panel A. 
Pharmacokinetic sampling was collected immediately before dosing 
and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, and 72 h after the dose.
Determination of MK-7246 and M3 concentrations in plasma. An ana-
lytical method for the simultaneous determination of MK-7246 (defini-
tive assay) and acyl glucuronide (M3) metabolite (exploratory assay) 
in human plasma was developed and validated over the concentration 
ranges of 0.5–500 ng/ml and 5.0–500 ng/ml, respectively. The analytes 
were isolated through protein precipitation extraction in a 96-well for-
mat with a 100 µl acidified plasma sample fortified with 50 µl of stable 
isotope-labeled internal standard. An aliquot of the supernatant was 
analyzed using reverse-phase high-performance liquid chromatography 
(Acquity UPLC; Waters, Milford, MA) with tandem mass spectrometric 
(API4000; Applied Biosystems Sciex, Concord, Ontario, Canada) detec-
tion fitted with a turbo ionspray interface. Multiple-reaction monitoring 
of the precursor to product ion pairs was used for quantification. The 
mean correlation coefficients (R2) were 0.9972 for MK-7246 and 0.9964 
for M3. The intraday and interday coefficients of variation were ≤7.0% 
for MK-7246 and for M3 across all standard concentrations.
Pharmacokinetics. The pharmacokinetics of MK-7246 and its metabo-
lite M3 were estimated by means of noncompartmental analysis using 
WinNonlin 5.0.1 (Pharsight, Mountain View, CA). Concentrations of 
the two analytes in plasma and nominal sampling times were used to 
estimate pharmacokinetic parameters in each subject. AUC0–∞ was 
calculated using the linear trapezoidal method for ascending concen-
trations and the log trapezoidal method for descending concentra-
tions. The extrapolated portion of the AUC from the last time point 
of sample collection (tlast) to infinity was determined by dividing the 
observed concentration at tlast (Clast) by the terminal rate constant (k). 
AUC0–∞ was then calculated from the sum of the AUC through the last 
measured time point (AUClast) and the extrapolated area. The value of 
k was determined from the slope of a least-squares fit to the terminal 
phase of the log-transformed concentration–time curve. The t1/2 was 
then calculated from the equation t1/2 = ln (2)/k. The Cmax and tmax 
were obtained by inspection of the plasma concentration–time data.
Reagents. MK-7246 and its acyl glucuronide metabolite were syn-
thesized by Merck Research Laboratories (Rahway, NJ). Baculovirus-
expressed human UGTs 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 
2B4, 2B7, 2B15, and 2B17, and control supersomes, and pooled HLMs 
were obtained from BD Gentest (Woburn, MA). Pooled HIMs were 
purchased from XenoTech (Lenexa, KS).
Quantification of the acyl glucuronide M3. To determine the UGT iso-
forms capable of metabolizing MK-7246 to M3, the formation of M3 
was measured by incubating HLMs and UGT supersomes (1 mg/ml) 
in  50 mmol/l  phosphate  buffer  (pH  7.4)  with  1 mmol/l  magnesium 
chloride,  alamethicin  (0.025 mg/ml),  D-saccharic  acid-1,4-lactone 
(2.5 mmol/l), and MK-7246 (5 or 50 μmol/l). The reactions were initi-
ated by adding 4 mmol/l uridine 5′-diphosphate-glucuronic acid and 
were then terminated after 90 min at 37 °C by adding two volumes of 
acetonitrile containing internal standard (labetalol) and 0.1% formic 
acid. The samples were centrifuged and analyzed using liquid chroma-
tography–tandem mass spectrometry. High-performance liquid chro-
matography separation was performed on a Fluophase PFP column 
(50 × 3 mm, 5 μm; Thermo-Electron, Waltham, MA) using aqueous articles
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0.1% formic acid and acetonitrile containing 0.1% formic acid as the 
mobile phase and operated at a flow rate of 0.5 ml/min for 9.5 min. 
Tandem mass spectrometry analysis was performed on a TSQ Quantum 
mass spectrometer (Thermo-Electron) using electrospray ionization 
in the positive ion mode. The transitions monitored were: m/z 417.1 
→ 228.1 for MK-7246, m/z 593.0 → 371.0 for MK-7246 glucuronide, 
and m/z 329.0 → 162.0 for labetalol. The range of quantification was 
0.05–10 μmol/l. The relative amounts of M3 formation were assessed on 
the basis of the peak area ratios relative to the internal standard.
enzyme kinetics for MK-7246 glucuronidation. MK-7246 glucuronida-
tion kinetics with HLMs, HIMs, and recombinant human UGT1A1, 
1A3,  1A8,  1A9,  2B7,  and  2B17  were  performed  over  a  range  of 
MK-7246  concentrations  (0.5–400 μmol/l)  using  conditions  similar 
to those described above except that linear conditions were used with 
respect to protein concentrations (Table 1) and incubation times. The 
reactions were terminated after 30 min of incubation. For determin-
ing the kinetic parameters, MK-7246 concentration and velocity data 
for MK-7246 glucuronidation were fitted to the standard Michaelis–
Menten model to obtain the Vmax and Km. SigmaPlot version 10.0 
(Systat Software, San Jose, CA) was used for the model fitting.
Genotyping.  Clinical  samples  of  DNA  were  extracted  from  200 μl 
of  ethylenediaminetetraacetic  acid–anticoagulated  blood  using  the 
Agencourt Genfind v2 DNA purification system (Beckman Coulter 
Genomics,  Danvers,  MA)  in  accordance  with  the  manufacturer’s 
instructions. Control HapMap DNA samples with known UGT2B17 
copy-number variation were purchased as purified DNA from the 
Coriell Institute for Medical Research. The subjects were genotyped 
for the UGT2B17 deletion using two TaqMan copy-number assays 
obtained from Applied Biosystems (Foster City, CA): Hs03185327 and 
Hs04282679. The results from both assays were concordant for all sam-
ples and gave correct genotypes for HapMap controls.
statistical analysis. A recessive inheritance model was assumed, based 
on the genetics. The UGT2B17*1/*1 genotype and the UGT2B17*1/*2 
genotype were combined (≥1 copy number) and compared with the 
recessive UGT2B17*2/*2 genotype (0 copy number). Fisher’s exact test 
was used to examine the high vs. low pharmacokinetic responders by 
genotype. Sensitivity analyses were performed by examining the geno-
types as belonging to three distinct categories, pooled into two groups 
to  represent  the  recessive  inheritance  models.  One-way  analysis  of 
variance models with genotype also confirmed the nonparametric tests 
when the pharmacokinetic end point was dichotomized into the catego-
ries of high and low responders.
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